Core Viewpoint - The approval of additional specifications for tadalafil tablets by the National Medical Products Administration is expected to enhance the product line of the company, although it is not anticipated to have a significant impact on recent performance due to uncertainties in drug sales [1] Group 1: Product Approval - The company has received approval for tadalafil tablets in 2.5mg and 5mg specifications [1] - Tadalafil is used for the treatment of erectile dysfunction [1] Group 2: Financial Impact - The estimated sales revenue for tadalafil in domestic sample hospitals is approximately 142.72 million yuan for 2024 [1] - The company has invested around 11.95 million yuan in the research and development of this drug [1] Group 3: Future Prospects - In 2025, the company is expected to obtain 11 varieties, 13 production licenses, and 2 clinical licenses [1] - The approval is seen as a way to enrich the product line, but the sales of the drug remain uncertain [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received approval from the National Medical Products Administration for the supplemental application of Tadalafil tablets, allowing for the introduction of new specifications [1] Group 1: Product Approval - The approval includes the addition of 2.5mg and 5mg specifications for Tadalafil tablets [1] - Tadalafil is primarily used for the treatment of erectile dysfunction in both 2.5mg and 5mg specifications, and for the treatment of erectile dysfunction combined with benign prostatic hyperplasia only in the 5mg specification [1]

（文章来源：证券日报） 证券日报网讯 11月13日晚间，联环药业发布公告称，公司于近日收到公司间接股东扬州产业投资发展 集团有限责任公司（简称"产发集团"）的通知，扬州市人民政府国有资产监督管理委员会已将其所持产 发集团6.45%的股权无偿划转至江苏省财政厅。截至本公告披露日，公司间接股东产发集团相关工商变 更登记手续已办理完成。 ...

证券代码：600513 证券简称：联环药业 公告编号：2025-085 江苏联环药业股份有限公司 特此公告。 关于公司间接股东股权结构变动完成的公告 江苏联环药业股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 11 月 14 日 江苏联环药业股份有限公司（以下简称"联环药业"或"公司"）于近日收 到公司间接股东扬州产业投资发展集团有限责任公司（以下简称"产发集团"） 的通知，扬州市人民政府国有资产监督管理委员会已将其所持产发集团 6.45%的 股权无偿划转至江苏省财政厅。具体内容详见公司于 2025 年 11 月 8 日在上海证 券交易所网站（http://www.sse.com.cn）和指定信息披露媒体披露的《联环药 业关于控股股东股权结构变动的提示性公告》（公告编号：2025-083）。 截至本公告披露日，公司间接股东产发集团相关工商变更登记手续已办理完 成。 敬请广大投资者理性投资，注意投资风险。 ...

联环药业(600513.SH)公告称，公司间接股东扬州产业投资发展集团有限责任公司的工商变更登记手续 已办理完成，扬州市人民政府国有资产监督管理委员会已将其所持产发集团6.45%的股权无偿划转至江 苏省财政厅。 ...

Group 1 - The stock of Lianhuan Pharmaceutical (600513) increased by 7.48% with a turnover rate of 15.55% and a transaction amount of 999 million yuan, showing a volatility of 15.23% on the day [2] - The stock was listed on the Shanghai Stock Exchange's daily volatility board due to its 15.23% fluctuation, with a net buying amount of 21.85 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 173 million yuan, with a buying amount of 97.28 million yuan and a selling amount of 75.43 million yuan, resulting in a net buying of 21.85 million yuan [2] Group 2 - The leading buying and selling brokerage seats were both from Guotai Junan Securities Co., Ltd. headquarters, with a buying amount of 34.60 million yuan and a selling amount of 21.81 million yuan [2] - Over the past six months, the stock has appeared on the volatility board 10 times, with an average price increase of 1.79% the next day and an average increase of 6.73% over the following five days [2] - On October 25, the company reported a revenue of 2.08 billion yuan for the first three quarters, representing a year-on-year growth of 26.63%, while the net profit was -35.06 million yuan [2]

关于公司原料药产品左炔诺孕酮通过世界卫生组织 证券代码：600513 股票简称：联环药业 公告编号：2025-084 江苏联环药业股份有限公司 预认证现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到世界卫生组织 （WHO）通知。世界卫生组织预认证团队对公司原料药产品左炔诺孕酮 （APIMF484,WHOAPI-484）（以下简称"该产品"）的现场检查现已关闭，结果 为符合世界卫生组织良好生产规范（GMP）的标准。现将相关情况公告如下： 一、GMP现场检查相关信息 企业名称：江苏联环药业股份有限公司 生产地址：江苏省扬州市扬州生物健康产业园健康一路 9 号 检查范围：合成区：C7-H5 生产线、C4-H3 生产线；洁净区：C4 厂房 6 号洁 净区 检查时间：2025.03.10—2025.03.13 检查结论：世界卫生组织预认证团队对公司原料药产品左炔诺孕酮 （APIMF484,WHOAPI-484）的现场检查现已关闭，结果为符合世界卫生组织良好 生产规范（ ...

Market Overview - On November 10, the Jiangsu state-owned enterprise reform sector rose by 1.09% compared to the previous trading day, with Xuelang Environment leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Stock Performance - Xuelang Environment (300385) closed at 6.28, with a gain of 4.49% and a trading volume of 270,400 shares, amounting to a transaction value of 171 million [1] - Jianshi Family (603369) closed at 39.22, up 3.78%, with a trading volume of 168,300 shares and a transaction value of 651 million [1] - Jiangtian Chemical (300927) closed at 28.69, up 3.72%, with a trading volume of 90,700 shares and a transaction value of 257 million [1] - Other notable stocks include Weivi Co. (600300) with a 3.63% increase and a transaction value of 269 million, and Jiangsu Jinzu (600901) with a 3.57% increase and a transaction value of 261 million [1] Capital Flow - The Jiangsu state-owned enterprise reform sector saw a net inflow of 99.64 million from main funds, while retail investors experienced a net outflow of 81.07 million [2] - The main funds showed a significant presence in stocks like Huatai Securities (601688) with a net inflow of 154 million, while retail investors withdrew from stocks like Xuelang Environment and Weivi Co. [3]

Core Points - The company received notification from the World Health Organization (WHO) regarding the successful closure of the on-site inspection for its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHOAPI-484) [1] - The inspection results indicate that the company's production line complies with WHO Good Manufacturing Practice (GMP) standards, which is beneficial for maintaining stable product quality and production capacity to meet market demand [1] - The successful WHO pre-certification inspection is not expected to have a significant impact on the company's recent performance [1]

Core Viewpoint - The company received notification from the World Health Organization that its raw material drug product, Levonorgestrel, has passed the site inspection, meeting the WHO's good manufacturing practice standards [1] Group 1: Inspection Details - The inspection took place from March 10 to March 13, 2025, covering the synthesis area and part of the cleanroom production lines [1] - The successful inspection is expected to help maintain product quality and production capacity [1] Group 2: Financial Impact - The inspection results are not expected to have a significant impact on the company's recent performance [1] - The drug master file review has not been closed, indicating uncertainty regarding future procurement [1]